Tukysa (tucatinib) may represent a new patient-friendly option as a first line maintenance treatment possibility for patients ...
HER2CLIMB-05 trial evaluated Tukysa in combination with Herceptin and Perjeta for HER2-positive metastatic breast cancer, ...
Researchers have identified chromosomal instability in circulating tumour cells as a prognostic and predictive biomarker in ...
A potential option for patients who do not have access to neoadjuvant immunotherapy Triple negative breast cancer is an aggressive subtype of breast cancer marked by higher rates of relapse and ...
San Diego, CA, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Sapu BioScience today announced the publication of a new peer-reviewed study in the International Journal of Molecular Sciences that strengthens the ...
The FDA approved T-DXd plus pertuzumab for HER2-positive metastatic breast cancer, based on DESTINY-Breast09 trial results. The combination therapy reduced disease progression or death risk by 44% ...
T-DXd plus pertuzumab improved quality-of-life outcomes, with fewer skin and mucosal symptoms but more gastrointestinal issues compared to the standard regimen. Both treatment arms showed similar pain ...
Phase 1 data demonstrates durable responses and rPFS coupled with a manageable safety profile rPFS of 7.9-8.9 months in heavily pre-treated mCRPC patients Preliminary results are encouraging with deep ...
Among breast cancer patients with a high recurrence score, the 5-year disease-free interval rate was 96.1% for patients received anthracyclines and 91.0% for those who did not. Adding anthracyclines ...
Among breast cancer patients with a high recurrence score, the 5-year disease-free interval rate was 96.1% for patients received anthracyclines and 91.0% for those who did not. These findings come ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback